Hawthorn for Heart Failure

Heart Failure — scientific infographic poster

Hawthorn (Crataegus monogyna, C. oxyacantha, C. pinnatifida) is the only herbal medicine for which Germany's Commission E granted a formal regulatory approval for a serious cardiovascular indication: New York Heart Association Class II congestive heart failure. The standardized leaf-and-flower extract WS 1442 has been tested in two pivotal placebo-controlled trials — HERB CHF in 2009 (Zick et al., 120 patients) and the much larger SPICE trial in 2008 (Holubarsch et al., 2,681 patients) — on top of standard heart failure pharmacotherapy. In laboratory tests on human heart muscle, the extract strengthened contraction by a route its researchers likened to the cAMP-independent action of cardiac glycosides such as digoxin; oligomeric proanthocyanidins (OPCs) and flavonoids in the extract are also described as widening blood vessels and acting as antioxidants. This deep-dive examines the pivotal trials, the mechanism behind the inotropic effect, where Hawthorn fits in the modern guideline-directed medical therapy (GDMT) stack of angiotensin-converting enzyme inhibitors (ACE inhibitors) and beta-blockers, and what is known about its safety.


Table of Contents

  1. Congestive Heart Failure — The Clinical Context
  2. German Commission E Approval for NYHA Class II
  3. The Standardized Extract WS 1442
  4. The HERB CHF 2009 Trial (Zick et al.)
  5. The SPICE Trial — 2,681 Patients (Holubarsch 2008)
  6. The Inotropic Mechanism — OPCs and Flavonoids
  7. Comparison to Digoxin
  8. Comparison to ACE Inhibitors and Beta-Blockers
  9. Practical Dosing and Standardized Products
  10. Monitoring, Cautions, and Drug Interactions
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Congestive Heart Failure — The Clinical Context

Congestive heart failure (CHF) is the syndrome that results when the heart cannot pump enough blood to meet the body's metabolic demands at normal filling pressures. Roughly 6.7 million American adults carry the diagnosis, and the lifetime risk at age 40 approaches 20%. The most common etiologies are prior myocardial infarction with resulting left ventricular dysfunction, long-standing hypertension, valvular heart disease, and idiopathic dilated cardiomyopathy. The clinical presentation is dyspnea on exertion (the lung component), peripheral edema (the fluid-retention component), and exercise intolerance (the cardiac-output component).

The New York Heart Association (NYHA) functional classification stratifies CHF severity in a way that is directly clinically relevant to Hawthorn use:

The natural history of untreated CHF is grim — historically, the one-year mortality rate after diagnosis approached 25-30%. Modern guideline-directed medical therapy (GDMT) has dramatically improved this, but heart failure remains a leading cause of hospitalization in Americans over 65, and the burden of symptoms, fatigue, and limited exercise tolerance continues to substantially affect quality of life. In older trials pooled by a 2008 Cochrane review, hawthorn extract added to conventional treatment raised maximal exercise workload (by 5.35 watts on average) and improved symptoms such as shortness of breath and fatigue. The HERB CHF trial, which added hawthorn to contemporary heart failure therapy, concluded that hawthorn "provides no symptomatic or functional benefit when given with standard medical therapy to patients with heart failure", and it recorded significantly more adverse events in the hawthorn group (P = 0.02), most of them not heart-related.

Back to Table of Contents

German Commission E Approval for NYHA Class II

The German Commission E was a scientific advisory board to the German federal health agency (BfArM) that, between 1978 and 1994, evaluated approximately 300 medicinal plants for safety and efficacy and issued formal monographs governing their use as medicines. Of those 300, only a small subset received formal approval for serious cardiovascular indications, and Hawthorn leaf-and-flower preparations were the most prominent.

The Commission E monograph for Crataegus folium cum flore (Hawthorn leaf with flower), published in 1984 and reaffirmed multiple times since, approved the standardized extract for "decreasing cardiac output as described as functional Stage II of the NYHA classification." The approved dose was 160-900 mg native water-ethanol extract per day (4-7:1 drug-to-extract ratio, standardized to OPC content). The monograph noted that the effect manifests slowly and that the patient should be told to expect a delay of approximately 6-8 weeks before symptomatic benefit is apparent — the same time-course that modern trials have confirmed.

The Commission E monograph for Hawthorn berries (Crataegus fructus), in contrast, was negative — the berry preparations lacked the OPC and flavonoid content of leaf-and-flower preparations and showed no evidence of efficacy. This is an important clinical point: products labeled simply "Hawthorn" or based on berry extracts alone are not the preparations that have efficacy data behind them. The well-studied product is always specifically the leaf-and-flower extract.

The European Medicines Agency (EMA) Committee on Herbal Medicinal Products has subsequently incorporated the Commission E findings into a Europe-wide herbal monograph for Hawthorn leaf with flower, listing it as a "traditional herbal medicinal product used to relieve symptoms of temporary nervous cardiac complaints (e.g. palpitations, perception of heart beat due to anxiety), after serious conditions have been excluded by a medical doctor." In its current summary, the EMA's herbal committee accepts hawthorn leaf and flower only on the basis of "traditional use" — for temporary heart complaints related to nervousness, such as palpitations (after serious conditions have been ruled out by a doctor), for mild symptoms of mental stress and to aid sleep. The committee "noted a lack of clinical studies with hawthorn leaf and flower medicines"; it grants no well-established use and no heart-failure use.

Back to Table of Contents

The Standardized Extract WS 1442

Nearly all of the modern Hawthorn clinical trial data uses one specific extract: WS 1442, a German standardized extract. WS 1442 is a 4-7:1 ethanol-water (45% w/w) extract of Crataegus monogyna and/or C. oxyacantha leaves and flowers, standardized to:

In Germany the extract is sold over the counter. In the United States, products marketed as "Hawthorn extract standardized to OPCs and flavonoids" that match these specifications can be considered roughly equivalent, but the bioactivity of individual commercial preparations varies substantially. The American Herbal Pharmacopoeia has published a Hawthorn monograph with standardization specifications that broadly track the WS 1442 profile.

The reason standardization matters so much here is that the dose-response curve for OPCs and flavonoids is fairly steep, and unstandardized whole-herb capsules or tinctures may contain anywhere from 0.5% to 5% of the active OPC content of WS 1442. Generic "Hawthorn berry" products from a supermarket are not the preparation tested in the SPICE or HERB CHF trials. Those trials used 900 mg/day of standardized leaf-and-flower extract, and the Commission E monograph describes an effect that appears slowly, over about 6-8 weeks.

Back to Table of Contents

The HERB CHF 2009 Trial (Zick et al.)

HERB CHF (Hawthorn Extract Randomized Blinded Chronic Heart Failure) was a US-based double-blind placebo-controlled trial published by Suzanna Zick and colleagues at the University of Michigan in the European Journal of Heart Failure in 2009. It enrolled 120 patients with NYHA Class II-III heart failure on standard pharmacotherapy (angiotensin-converting enzyme inhibitor (ACE inhibitor) and/or beta-blocker, diuretic) and randomized them to either 450 mg WS 1442 twice daily or matched placebo for 6 months.

The primary endpoint was change in 6-minute walk distance — a standard physical-function test in heart failure trials. Secondary endpoints included quality of life (Minnesota Living with Heart Failure Questionnaire), NYHA classification, and left ventricular ejection fraction by echocardiogram.

The results were modestly disappointing relative to earlier European studies:

The authors concluded: "Hawthorn provides no symptomatic or functional benefit when given with standard medical therapy to patients with heart failure." A second analysis of the same HERB CHF patients (Zick, Gillespie and Aaronson, 2008) looked at worsening heart failure over the 6 months — heart-failure death, hospital admission, or a lasting increase in water pills (diuretics). It happened in 46.6% of the hawthorn group and 43.3% of the placebo group, a difference that was not significant. Early in the study, though, people taking hawthorn were 3.9 times more likely to worsen (95% confidence interval 1.1-13.7; 6.4 times after adjustment), and among patients with an ejection fraction of 35% or less the risk was 3.2 times that of placebo. The authors concluded that the extract does not reduce heart failure progression and "appears to increase the early risk of HF progression".

The HERB CHF results stand in contrast to the larger body of European trials that have generally shown positive effects on exercise tolerance and quality of life. Several explanations have been offered: the trial may have been underpowered to detect the modest effect size that earlier work suggested; the US patient population was older, sicker, and more medically optimized (almost all on angiotensin-converting enzyme inhibitors and beta-blockers, more so than in older European trials); and the small number of cardiovascular events makes the safety signal hard to interpret.

The HERB CHF results were a useful corrective to optimistic interpretations of earlier trials and suggested that the marginal benefit of Hawthorn on top of fully optimized modern heart failure therapy may be smaller than was apparent against the older background of less complete pharmacotherapy. The trial did not, however, refute the larger pool of European efficacy data, and the SPICE trial published a year earlier provides the most authoritative single dataset.

Back to Table of Contents

The SPICE Trial — 2,681 Patients (Holubarsch 2008)

SPICE (Survival and Prognosis Investigation of Crataegus Extract WS 1442 in Congestive Heart Failure) was the definitive Hawthorn clinical trial — the largest, most rigorous, and most clinically informative ever conducted. Christian Holubarsch and colleagues enrolled 2,681 patients with NYHA Class II or III heart failure and left ventricular ejection fraction less than or equal to 35% and randomized them (1,338 to WS 1442, 1,343 to placebo) to either 900 mg/day WS 1442 or matched placebo, on top of guideline-directed standard therapy, for 24 months.

The primary endpoint was time to first cardiac event (defined as cardiac death, non-fatal myocardial infarction, hospitalization for heart failure progression). Secondary endpoints included all-cause mortality, cardiac mortality, and quality of life measures.

Headline results:

The authors concluded that WS 1442 "had no significant effect on the primary endpoint" but "was safe to use in patients receiving optimal medication for heart failure", and that the data may indicate a possible reduction in sudden cardiac death in patients with less compromised heart function. The interpretation has been debated. The trial did not demonstrate that adding Hawthorn to optimized GDMT prolongs life or prevents heart failure hospitalization in unselected NYHA II-III patients. However, the subgroup signal for reduced sudden cardiac death in patients with LVEF 25-35% is biologically plausible (Hawthorn flavonoids have documented anti-arrhythmic effects through prolongation of the cardiac effective refractory period) and clinically meaningful if real — sudden cardiac death is the leading cause of death in this population.

The combination of HERB CHF and SPICE suggests that Hawthorn's clinical role in 2026 is not as a replacement for or a strong adjunct to GDMT in advanced systolic dysfunction. Rather, practitioners who use it place it with milder symptoms (NYHA Class II), for people who want to add a well-tolerated, multi-mechanism cardiotonic to their regimen for symptom improvement and modest exercise-tolerance gain — precisely the population for which Commission E approved it.

Back to Table of Contents

The Inotropic Mechanism — OPCs and Flavonoids

The cellular mechanism by which Hawthorn increases cardiac contractility has been compared with that of the better-known cardiac glycoside digoxin. Digoxin inhibits the Na+/K+-ATPase pump on the cardiomyocyte membrane, which secondarily increases intracellular sodium, which slows the activity of the Na+/Ca2+ exchanger, which raises intracellular calcium, which increases contractility. This mechanism has a narrow therapeutic window because the same Na+/K+-ATPase inhibition produces toxic effects (arrhythmia, AV block, visual disturbance) at concentrations only modestly above the therapeutic range.

Laboratory studies of hawthorn extract in isolated heart muscle and perfused heart preparations describe several actions:

The net effect is a gentle inotropic boost (typically 10-15% in animal models, less in human studies) with concurrent anti-arrhythmic and coronary vasodilator effects reported in laboratory studies. The complementary antioxidant cardioprotection from OPC scavenging of reactive oxygen species adds a fourth axis that no synthetic inotrope provides.

Back to Table of Contents

Comparison to Digoxin

Digoxin remains in the modern heart failure armamentarium, but its role has been substantially reduced over the past two decades. The Digitalis Investigation Group (DIG) trial in 1997 showed that digoxin reduced heart failure hospitalizations but did not improve mortality, and subsequent analysis suggested possible harm at higher serum levels. Current ACC/AHA guidelines reserve digoxin for symptomatic patients on optimized GDMT who continue to have heart failure symptoms or who have concurrent atrial fibrillation requiring rate control.

Compared to digoxin, Hawthorn has several advantages and one significant disadvantage:

In modern practice, Hawthorn is rarely a direct substitute for digoxin. Rather, practitioners use it in the much larger population of patients with mild symptomatic heart failure who do not yet meet criteria for digoxin, as a cardiotonic addition to their angiotensin-converting enzyme inhibitor and beta-blocker.

Back to Table of Contents

Comparison to ACE Inhibitors and Beta-Blockers

Modern guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF) is built on four foundational drug classes:

  1. Angiotensin-converting enzyme inhibitors (lisinopril, enalapril, ramipril) or angiotensin receptor blockers (ARBs) or the combination ARNi sacubitril-valsartan — afterload reduction, neurohormonal modulation
  2. Beta-blockers (carvedilol, metoprolol succinate, bisoprolol) — sympathetic blockade, anti-arrhythmic, remodeling reversal
  3. Mineralocorticoid receptor antagonists (spironolactone, eplerenone) — aldosterone blockade, anti-fibrotic, hypokalemia prevention
  4. Sodium-glucose cotransporter-2 (SGLT2) inhibitors (empagliflozin, dapagliflozin) — the newest class; they reduce the risk of heart-failure hospitalization and cardiovascular death in HFrEF (ejection fraction 40% or less). In mildly reduced or preserved ejection fraction (HFpEF), the DELIVER trial of dapagliflozin (6,263 patients) found a lower combined risk of worsening heart failure or cardiovascular death (16.4% vs 19.5%, hazard ratio 0.82), mainly from fewer worsening-heart-failure events; cardiovascular death alone did not fall significantly (7.4% vs 8.3%, hazard ratio 0.88, 95% confidence interval 0.74-1.05)

Each of these has Class I guideline recommendation with multiple positive mortality trials. None can be displaced by Hawthorn — the magnitude of mortality benefit from optimized GDMT is substantially larger than anything Hawthorn has demonstrated.

Hawthorn's role is therefore explicitly adjunctive. The positioning described by practitioners who use it is:

The older positive evidence comes from a 2008 Cochrane review (Pittler, Guo and Ernst) of 14 double-blind, placebo-controlled trials of hawthorn leaf-and-flower extract, mostly used alongside conventional treatment. Ten trials with 855 patients (NYHA Class I to III) could be pooled. Maximal workload rose by 5.35 watts on average (95% confidence interval 0.71-10.00), and shortness of breath and fatigue improved significantly compared with placebo. Apart from one trial, which reported deaths (three on hawthorn, one on placebo) without further details, the trials reported no data on deaths or cardiac events. Reported side effects were infrequent, mild and short-lived.

Hawthorn is one of the few herbal additions to GDMT with a formal approval (German Commission E, NYHA Class II) and supportive trial data (the older trials above and a SPICE subgroup signal). The European Medicines Agency accepts it only as a traditional medicine for nervous heart complaints, and the HERB CHF trial found no added benefit on top of contemporary therapy. The Blood Pressure deep-dive covers people with mild hypertension as well as mild heart failure.

Back to Table of Contents

Practical Dosing and Standardized Products

The dose used in the SPICE and HERB CHF trials, and the European practice around it:

Products sold in the United States as matching the WS 1442 specification include pharmacy-grade German imports. The trial preparation was made from leaf and flower (not berry), standardized to OPCs and flavonoids, and the trial dose of 900 mg/day refers to the extract, not to 900 mg/day of crude herb; product labels state these details.

Hawthorn berry tea is a traditional, gentle wellness practice, but it is not the preparation tested in the trials. Berry preparations were specifically excluded from the Commission E approval because they lack the OPC content of leaf-and-flower preparations.

Back to Table of Contents

Monitoring, Cautions, and Drug Interactions

Back to Table of Contents

Key Research Papers

  1. Holubarsch CJF et al. (2008). The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. European Journal of Heart Failure 10(12):1255-1263. — PubMed PMID: 19019730
  2. Zick SM, Vautaw BM, Gillespie B, Aaronson KD (2009). Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial. European Journal of Heart Failure 11(10):990-999. — PubMed PMID: 19789403
  3. Zick SM, Gillespie B, Aaronson KD (2008). The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. European Journal of Heart Failure 10(6):587-593. — PubMed PMID: 18490196
  4. Pittler MH, Guo R, Ernst E (2008). Hawthorn extract for treating chronic heart failure. Cochrane Database Syst Rev. — PubMed PMID: 18254076
  5. Tauchert M (2002). Efficacy and safety of Crataegus extract WS 1442 in comparison with placebo in patients with chronic stable NYHA Class III heart failure. American Heart Journal 143(5):910-915. — PubMed PMID: 12040357
  6. Schwinger RHG et al. (2000). Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. J Cardiovasc Pharmacol 35(5):700-707. — PubMed PMID: 10813370
  7. Eichstädt H et al. (1989). Cardiac efficacy of Crataegus oxyacantha special extract WS 1442 in NYHA II patients. Therapiewoche 39:3288-3296. — PubMed
  8. Weikl A et al. (1996). Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II). Fortschr Med 114(24):291-296. — PubMed PMID: 8974970
  9. Tankanow R et al. (2003). Interaction study between digoxin and a preparation of hawthorn. J Clin Pharmacol 43(6):637-642. — PubMed PMID: 12817526
  10. Loew D (1997). Phytotherapy in heart failure. Phytomedicine 4(3):267-271. — PubMed PMID: 23195488
  11. Brixius K et al. (2006). Crataegus special extract WS 1442 induces an endothelium-dependent, NO-mediated vasorelaxation. Cardiovasc Drugs Ther 20(3):177-184. — PubMed PMID: 16779533
  12. Veveris M et al. (2004). Crataegus special extract WS 1442 improves cardiac function and reduces infarct size in a pig model of acute myocardial infarction. Life Sci 74(15):1945-1955. — PubMed
  13. Tauchert M, Gildor A, Lipinski J (1999). High-dose Crataegus extract WS 1442 in comparison with placebo in NYHA II patients with heart failure. Herz 24(6):465-474. — PubMed
  14. Solomon SD, McMurray JJV, Claggett B, et al.; DELIVER Trial Committees and Investigators (2022). Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England Journal of Medicine 387(12):1089-1098. — PubMed PMID: 36027570
  15. European Medicines Agency, Committee on Herbal Medicinal Products. Crataegi folium cum flore (hawthorn leaf and flower): herbal medicine summary. — ema.europa.eu

PubMed Topic Searches

  1. PubMed: Crataegus heart failure
  2. PubMed: Hawthorn WS 1442 inotropic
  3. PubMed: Crataegus NYHA II
  4. PubMed: Hawthorn digoxin interaction
  5. PubMed: Crataegus ejection fraction

Back to Table of Contents

Connections

Back to Table of Contents